Research programme: ISS-grass pollen conjugates - DynavaxAlternative Names: ISS-grass pollen conjugates research programme - Dynavax
Latest Information Update: 06 Aug 2007
At a glance
- Originator Dynavax Technologies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 22 Mar 2005 Dynavax's ISS-grass pollen conjugates programme is no longer licensed to UCB worldwide
- 24 Oct 2003 Preclinical trials in Seasonal allergic rhinitis in USA (Injection)